1-5 of 5
Jessica R. Flynn
Close
Sort by
Journal Articles

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Michael Scordo, Jessica R. Flynn, Mithat Gonen, Sean M. Devlin, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L. Porter, Stephen J. Schuster, Veronika Bachanova, Joseph Maakaron, Richard T. Maziarz, Andy I. Chen, Loretta J. Nastoupil, Joseph P. McGuirk, Olalekan O. Oluwole, Andrew Ip, Lori A. Leslie, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5579–5585.
https://doi.org/10.1182/bloodadvances.2023010302
Published: 2023
Includes: Supplemental data
Journal Articles

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Clinical Trials & Observations
Kitsada Wudhikarn, Ana Alarcon Tomas, Jessica R. Flynn, Sean M. Devlin, Jamie Brower, Veronika Bachanova, Loretta J. Nastoupil, Joseph P. McGuirk, Richard T. Maziarz, Olalekan O. Oluwole, Stephen J. Schuster, David L. Porter, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3192–3198.
https://doi.org/10.1182/bloodadvances.2022008294
Published: 2023
Includes: Supplemental data
Journal Articles

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation

Clinical Trials & Observations
Michael Scordo, Leah J. Gilbert, Danielle M. Hanley, Jessica R. Flynn, Sean M. Devlin, Linh K. Nguyen, Josel D. Ruiz, Gunjan L. Shah, Craig S. Sauter, David J. Chung, Heather J. Landau, Oscar B. Lahoud, Richard J. Lin, Parastoo B. Dahi, Miguel-Angel Perales, Sergio A. Giralt, Gerald A. Soff
Journal: Blood Advances
Blood Adv (2023) 7 (8): 1536–1544.
https://doi.org/10.1182/bloodadvances.2022007838
Published: 2023
Includes: Supplemental data
Journal Articles

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Clinical Trials & Observations
Martina Pennisi, Miriam Sanchez-Escamilla, Jessica R. Flynn, Roni Shouval, Ana Alarcon Tomas, Mari Lynn Silverberg, Connie Batlevi, Renier J. Brentjens, Parastoo B. Dahi, Sean M. Devlin, Claudia Diamonte, Sergio Giralt, Elizabeth F. Halton, Tania Jain, Molly Maloy, Elena Mead, Maria Lia Palomba, Josel Ruiz, Bianca Santomasso, Craig S. Sauter, Michael Scordo, Gunjan L. Shah, Jae H. Park, Lucrecia Yanez San Segundo, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3397–3406.
https://doi.org/10.1182/bloodadvances.2020003885
Published: 2021
Includes: Supplemental data
Journal Articles

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

Clinical Trials & Observations
Kitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio, Jessica R. Flynn, Aishat Afuye, Mari Lynne Silverberg, Molly A. Maloy, Sean M. Devlin, Connie Lee Batlevi, Gunjan L. Shah, Michael Scordo, Maria Lia Palomba, Parastoo B. Dahi, Craig S. Sauter, Bianca D. Santomasso, Elena Mead, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3024–3033.
https://doi.org/10.1182/bloodadvances.2020001972
Published: 2020
Includes: Supplemental data